
Injection: Adverse reactions were reported in 13 of 2,872 patients (0.45%). (At the end of the re-examination period).
Clinically significant adverse reactions (incidence unknown): Anaphylactoid reaction: Anaphylactoid reaction such as decrease in blood pressure or dyspnea, may occur. Patients should be carefully observed. In the event of such symptoms, Mecobalamin should be discontinued immediately and appropriate measures taken.
Other adverse reactions: See Table 6.

View ADR Reporting Link